未来医生 MedGPT 多中心研究:复杂肺癌病例中 88% 对比胜过医生
Future Doctor Says MedGPT Outscored Doctors in 88% of Comparisons on Complex Lung Cancer Cases
250 名医生、750 组对比,MedGPT 在 88% 的复杂肺癌病例判断上赢了独立诊断的医生。数字看着猛,但评分是 AI 打的、数据还是公司自报的,看看它怎么设计的多中心试验也挺有意思。
未来医生发布 MedGPT 多中心研究结果:在 40 例复杂肺癌病例上,MedGPT 辅助的判断在 750 组对比中 660 次优于医生独立判断,胜率约 88%,评分由 AI 评审完成,共有 250 名医生参与该研究。
研究采用多中心设计,覆盖 40 个疑难肺癌病例和 750 组配对比较,每组的评判由 AI 系统打分,而非人工评审。这一设计能大规模量化模型辅助诊断与医生独立判断的差距,但 AI 当裁判的公正性依赖于评分模型本身的能力。
需要留意的是,所有数据由未来医生自报,尚未经过独立第三方复核。医疗 AI 的对照研究结果通常需要同行评审和外部验证才能进入临床决策参考,此前 MedGPT 主要面向肺结节和肺癌辅助诊断场景。
Future Doctor Says MedGPT Outscored Doctors in 88% of Comparisons on Complex Lung Cancer Cases
Future Doctor says MedGPT beat unassisted doctors in 660 of 750 comparisons on 40 complex lung cancer cases, scored by AI judges. The figures are self-reported.
This report is categorized under AITOP's "Models" desk, focusing on China's AI industry and domestic foundation model ecosystem. Within our cross-regional analytical framework, it directly maps to AI developer toolchains, coding agents, and engineering workflows and US-China foundation model benchmarks and commercialization comparison. Key entities and technical topics under continuous tracking include MedGPT, medical AI.
Primary source verification: published directly by pandaily with first-party authority.